{"pmid":32441773,"title":"COVID-19 in a patient with HIV infection.","text":["COVID-19 in a patient with HIV infection.","The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved.","J Med Virol","Patel, Raj H","Pella, Pablo M","32441773"],"abstract":["The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Patel, Raj H","Pella, Pablo M"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441773","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26049","keywords":["covid-19","hiv","sars-cov-2","antiretroviral","co-infection"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667535119509880833,"score":9.490897,"similar":[{"pmid":32437000,"title":"HIV and SARS-CoV-2 co-infection: A case report from Uganda.","text":["HIV and SARS-CoV-2 co-infection: A case report from Uganda.","There are no reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HIV co-infection from sub-Saharan Africa where 70% of people living with HIV are found. We report a case of HIV/SARS-CoV-2 co-infection from Uganda. A 34 year old HIV-positive female on antiretroviral therapy (tenofovir disoproxil fumarate, lamivudine and efavirenz) for 5 years, tested positive for SARS-CoV-2, the causative agent for coronavirus disease 19 (COVID-19). She was asymptomatic at presentation but subsequently developed headache, chest pain, diarrhoea, anorexia and fatigue on day 3 of isolation without cough, fever or shortness of breath. Her CD4 count was 965 cells/mm(3) , the HIV viral load was undetectable (<1,000 cells/mm(3) ) and other laboratory work up was normal. She was successfully managed with hydroxychloroquine and broad spectrum antibiotics, and was discharged after 24 days. This case demonstrates an atypical clinical presentation of COVID - 19 in an HIV infected patient without other co-morbidity. This article is protected by copyright. All rights reserved.","J Med Virol","Baluku, Joseph Baruch","Mwebaza, Shem","Ingabire, Gloria","Nsereko, Chris","Muwanga, Moses","32437000"],"abstract":["There are no reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HIV co-infection from sub-Saharan Africa where 70% of people living with HIV are found. We report a case of HIV/SARS-CoV-2 co-infection from Uganda. A 34 year old HIV-positive female on antiretroviral therapy (tenofovir disoproxil fumarate, lamivudine and efavirenz) for 5 years, tested positive for SARS-CoV-2, the causative agent for coronavirus disease 19 (COVID-19). She was asymptomatic at presentation but subsequently developed headache, chest pain, diarrhoea, anorexia and fatigue on day 3 of isolation without cough, fever or shortness of breath. Her CD4 count was 965 cells/mm(3) , the HIV viral load was undetectable (<1,000 cells/mm(3) ) and other laboratory work up was normal. She was successfully managed with hydroxychloroquine and broad spectrum antibiotics, and was discharged after 24 days. This case demonstrates an atypical clinical presentation of COVID - 19 in an HIV infected patient without other co-morbidity. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Baluku, Joseph Baruch","Mwebaza, Shem","Ingabire, Gloria","Nsereko, Chris","Muwanga, Moses"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437000","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26044","keywords":["covid-19","hiv","sars-cov-2","uganda"],"locations":["Uganda","Uganda"],"countries":["Uganda"],"countries_codes":["UGA|Uganda"],"e_drugs":["Tenofovir","Hydroxychloroquine","efavirenz","Lamivudine"],"topics":["Case Report"],"weight":1,"_version_":1667521393570349056,"score":353.96902},{"pmid":32347975,"title":"HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey.","text":["HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey.","In December 2019, the causative agent of Coronavirus disease 2019 (COVID-19) was identified and named as SARS-CoV-2. Since then it has been spreading and severe form of the illness predominantly occurs in adults with advanced age or underlying comorbidities. The European AIDS Clinical Society states the lack of evidence for a higher COVID-19 infection rate among people living with HIV (PLHIV) and there is a few published literature on the course of COVID-19 co-infection in PLHIV. We described four HIV/SARS-CoV-2 co-infected patients with different characteristics. The impression is that comorbidities is an important factor in mortality in HIV/SARS-CoV-2 co-infected cases. This article is protected by copyright. All rights reserved.","J Med Virol","Altuntas Aydin, Ozlem","Kumbasar Karaosmanoglu, Hayat","Kart Yasar, Kadriye","32347975"],"abstract":["In December 2019, the causative agent of Coronavirus disease 2019 (COVID-19) was identified and named as SARS-CoV-2. Since then it has been spreading and severe form of the illness predominantly occurs in adults with advanced age or underlying comorbidities. The European AIDS Clinical Society states the lack of evidence for a higher COVID-19 infection rate among people living with HIV (PLHIV) and there is a few published literature on the course of COVID-19 co-infection in PLHIV. We described four HIV/SARS-CoV-2 co-infected patients with different characteristics. The impression is that comorbidities is an important factor in mortality in HIV/SARS-CoV-2 co-infected cases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Altuntas Aydin, Ozlem","Kumbasar Karaosmanoglu, Hayat","Kart Yasar, Kadriye"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347975","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25955","keywords":["hiv","sars-cov-2","co-infection"],"locations":["Istanbul","Turkey"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"topics":["Case Report"],"weight":1,"_version_":1666138494930518016,"score":352.37},{"pmid":32492188,"title":"A case of SARS-CoV-2 infection in an untreated HIV patient in Tokyo, Japan.","text":["A case of SARS-CoV-2 infection in an untreated HIV patient in Tokyo, Japan.","We report a 28-year-old male co-infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19) and human immunodeficiency virus (HIV). His clinical course of the COVID-19 pneumonia improved smoothly in 9 days; however, his immune status from HIV infection was not well-controlled due to a lack of antiretroviral therapy (ART). The HIV-1 viral load decreased during the acute phase and subsequently increased in the recovery phase. Antiretroviral therapy was given a month after the twice non-detections of SARS-CoV-2 to avoid immune reconstitution syndrome (IRIS). Previous reports suggest COVID-19 do not become more severe in untreated HIV patients than non-HIV patients. However, untreated HIV patients with COVID-19 should be followed up carefully for IRIS with ART. This article is protected by copyright. All rights reserved.","J Med Virol","Nakamoto, Takato","Kutsuna, Satoshi","Yanagawa, Yasuaki","Kanda, Kouhei","Okuhama, Ayako","Akiyama, Yutaro","Miyazato, Yusuke","Ide, Satoshi","Nakamura, Keiji","Yamamoto, Kei","Ohmagari, Norio","32492188"],"abstract":["We report a 28-year-old male co-infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19) and human immunodeficiency virus (HIV). His clinical course of the COVID-19 pneumonia improved smoothly in 9 days; however, his immune status from HIV infection was not well-controlled due to a lack of antiretroviral therapy (ART). The HIV-1 viral load decreased during the acute phase and subsequently increased in the recovery phase. Antiretroviral therapy was given a month after the twice non-detections of SARS-CoV-2 to avoid immune reconstitution syndrome (IRIS). Previous reports suggest COVID-19 do not become more severe in untreated HIV patients than non-HIV patients. However, untreated HIV patients with COVID-19 should be followed up carefully for IRIS with ART. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Nakamoto, Takato","Kutsuna, Satoshi","Yanagawa, Yasuaki","Kanda, Kouhei","Okuhama, Ayako","Akiyama, Yutaro","Miyazato, Yusuke","Ide, Satoshi","Nakamura, Keiji","Yamamoto, Kei","Ohmagari, Norio"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492188","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26102","keywords":["anti-retrovirus drug < antiviral agents","human immunodeficiency virus < virus classification","sars coronavirus < virus classification"],"locations":["Tokyo","Japan"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"topics":["Case Report"],"weight":1,"_version_":1668892169250799616,"score":315.38254},{"pmid":32462663,"title":"Clinical features and outcome of HIV/SARS-CoV-2 co-infected patients in the Bronx, New York City.","text":["Clinical features and outcome of HIV/SARS-CoV-2 co-infected patients in the Bronx, New York City.","Coronavirus disease 2019 (COVID-19) is a highly contagious disease with millions of people have been infected. However, there is limited data regarding clinical features, disease courses and outcomes of COVID-19 in patients with human immunodeficiency virus (HIV). Herein, we presented the demographic data, clinical characteristics and outcomes of nine confirmed COVID-19 patients with HIV infection admitted to our hospital located in south Bronx, New York City. Our study revealed very high mortality rate at 78%, which may contradict to the hypothesis that immunosuppression from HIV infection prevents against severe COVID-19. More research is needed to determine the impact of HIV on the clinical course of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Suwanwongse, Kulachanya","Shabarek, Nehad","32462663"],"abstract":["Coronavirus disease 2019 (COVID-19) is a highly contagious disease with millions of people have been infected. However, there is limited data regarding clinical features, disease courses and outcomes of COVID-19 in patients with human immunodeficiency virus (HIV). Herein, we presented the demographic data, clinical characteristics and outcomes of nine confirmed COVID-19 patients with HIV infection admitted to our hospital located in south Bronx, New York City. Our study revealed very high mortality rate at 78%, which may contradict to the hypothesis that immunosuppression from HIV infection prevents against severe COVID-19. More research is needed to determine the impact of HIV on the clinical course of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Suwanwongse, Kulachanya","Shabarek, Nehad"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462663","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26077","keywords":["covid-19","haart","hiv","sars-cov-2","mortality"],"locations":["Bronx","New York","Bronx","New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668079521238089728,"score":287.57352},{"pmid":32401359,"title":"Recovery from COVID-19 in two patients with coexisted HIV infection.","text":["Recovery from COVID-19 in two patients with coexisted HIV infection.","COVID-19 has become a global health concern. HIV-infected patients are particularly vulnerable to COVID-19 due to their immune-compromised status. The clinical manifestations and clinical outcomes of these patients are not clear. In this report, we presented two special COVID-19 patients with HIV infection and other comorbidities. We described the clinical characteristics, clinical manifestations, treatments and clinical outcomes of both patients. One patient with prior HIV-infection continued anti-HIV treatment when diagnosed with COVID-19. The other patient was newly diagnosed with HIV-infection when diagnosed with COVID-19 and had not begun anti-HIV treatment. Both patients were treated with anti-viral, antibiotics, oxygen treatment and supportive care and recovered from severe pneumonia. The experience of these two cases suggested that COVID-19 patients with HIV infection could still have satisfactory clinical outcomes following proper medical care. This article is protected by copyright. All rights reserved.","J Med Virol","Wu, Qiuji","Chen, Tielong","Zhang, Hongyan","32401359"],"abstract":["COVID-19 has become a global health concern. HIV-infected patients are particularly vulnerable to COVID-19 due to their immune-compromised status. The clinical manifestations and clinical outcomes of these patients are not clear. In this report, we presented two special COVID-19 patients with HIV infection and other comorbidities. We described the clinical characteristics, clinical manifestations, treatments and clinical outcomes of both patients. One patient with prior HIV-infection continued anti-HIV treatment when diagnosed with COVID-19. The other patient was newly diagnosed with HIV-infection when diagnosed with COVID-19 and had not begun anti-HIV treatment. Both patients were treated with anti-viral, antibiotics, oxygen treatment and supportive care and recovered from severe pneumonia. The experience of these two cases suggested that COVID-19 patients with HIV infection could still have satisfactory clinical outcomes following proper medical care. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wu, Qiuji","Chen, Tielong","Zhang, Hongyan"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401359","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jmv.26006","keywords":["covid-19","hiv","case report","outcome"],"topics":["Case Report"],"weight":1,"_version_":1666714494784503808,"score":282.0728}]}